PT-141 10 mg Peptide Sciences

PT-141 10 mg Peptide Sciences: How to Use

Palatin Technologies has developed Bremelanotide. This is a special peptide designed to increase libido and improve erection. It is considered a worthy analogue of Melanotan 2. Both women and men actively use it. Note that PT-141 10 mg Peptide Sciences is actively used by athletes and bodybuilders to improve the training process. Below we consider the features of the application, dosage and possible effects of use.

What are the effects of PT-141 10 mg Peptide Sciences

PT-141 10 mg Peptide Sciences is a synthetic peptide analogue of alpha-MSH. MSH stands for melanocyte-stimulating hormone. Melanocyte is an endogenous peptide hormone that is part of the group collectively known as melanocortins.

PT-141 10 mg Peptide Sciences acts in the body in the same way as a non-selective full agonist of the melanocortin receptor. Because it is a full agonist, continued use of this peptide will result in darkening of the skin and hair. By stimulating higher levels of melatonin, it affects skin colour and our ability to cope with UV rays.

That is why athletes use this tool to achieve maximum efficiency during training.

Side effects and contraindications

As with any medication, side effects can occur. The most common are nausea and vomiting, experienced by about 40% of the study participants. Nausea is more likely the first time the drug is used and becomes less of a problem with subsequent doses. However, up to 13% of those who experienced nausea actually needed treatment for nausea. Other possible side effects include flushing and headache.

Also pay attention to some contraindications. Women with high blood pressure should avoid taking PT-141 10 mg Peptide Sciences Bremelanotide, as it may temporarily raise blood pressure. It is also not recommended for women at risk of cardiovascular disease.

Women taking naltrexone for the treatment of alcohol dependence should not use PT-141 Bremelanotide due to drug-drug interactions. In addition, darkening of the skin and gums has been observed in some women in studies. Although rare, these changes are permanent.

Socket characteristics

Bremelanotide PT-141 10 mg Peptide Sciences for injection is supplied as a solution (liquid) in a pre-filled automatic subcutaneous (under the skin) injection device. It is usually given as needed, at least 45 minutes before sexual activity.

You and your doctor will determine the best time to inject Bremelanotide PT-141 10 mg Peptide Sciences based on how well the medication works for you and the side effects you experience.

Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Use bremelanotide PT-141 10 mg Peptide Sciences 10 mg injection exactly as directed. Do not use more or less of it or use it more often than prescribed by your doctor.

List of references

1. Diamond LE, Earle DC, Heiman JR, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-638.
2. Heiman JR, Rupp H, Jannini EA. Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE-INtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. J Sex Med. 2010;7(3):1157-1171.
3. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-59.
4. Diamond LE, Graziottin TM, Viosca SP, et al. Bremelanotide Study Group. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of Bremelanotide, a melanocortin receptor agonist, in women with a sexual dysfunction disorder. J Sex Med. 2006;3(3):517-525.
5. Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004;16(2):135-142.